## Mario Cottone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7910433/publications.pdf

Version: 2024-02-01

48315 109321 8,104 112 35 88 citations h-index g-index papers 112 112 112 11478 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease. Digestion, 2020, 101, 433-440.	2.3	13
2	A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. Digestive and Liver Disease, 2020, 52, 1461-1466.	0.9	16
3	Persistence on Anti-Tumour Necrosis Factor Therapy in OlderÂPatients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Drugs and Aging, 2020, 37, 383-392.	2.7	20
4	Psoriasis and Inflammatory Bowel Disease. Digestive Diseases, 2019, 37, 451-457.	1.9	41
5	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. Inflammatory Bowel Diseases, 2019, 25, 987-997.	1.9	17
6	Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. Expert Opinion on Biological Therapy, 2019, 19, 89-98.	3.1	31
7	Risk of Pneumonia Caused by Pneumocystis jiroveci in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities. Clinical Gastroenterology and Hepatology, 2019, 17, 571-572.	4.4	6
8	The Addition of an Immunosuppressant After Loss of Response to Anti-TNF $\hat{l}\pm$ Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. Inflammatory Bowel Diseases, 2018, 24, 394-401.	1.9	16
9	A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. Digestive and Liver Disease, 2018, 50, 1292-1298.	0.9	16
10	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2017, 49, 338-358.	0.9	42
11	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Digestive and Liver Disease, 2017, 49, 604-617.	0.9	47
12	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. Scandinavian Journal of Gastroenterology, 2017, 52, 1-7.	1.5	21
13	The biologics of ulcerative colitis. Expert Opinion on Biological Therapy, 2017, 17, 175-184.	3.1	12
14	Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?. Journal of Clinical Virology, 2017, 97, 1-3.	3.1	15
15	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants. Digestive and Liver Disease, 2017, 49, 157-162.	0.9	6
16	JC Virus and Lung Adenocarcinoma: Fact or Myth?. Anticancer Research, 2017, 37, 3311-3314.	1.1	6
17	Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center. Clinical Gastroenterology and Hepatology, 2016, 14, 914.	4.4	8
18	The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?. Journal of Crohn's and Colitis, 2016, 10, 1451-1451.	1.3	7

#	Article	IF	Citations
19	Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study. Digestive and Liver Disease, 2016, 48, 1314-1317.	0.9	6
20	The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?. Gastroenterology, 2016, 151, 211-212.	1.3	9
21	Course of Crohn's Disease. , 2016, , 31-42.		0
22	Medical Treatment of Perianal Crohn's Disease. , 2016, , 49-58.		0
23	An update on medical management on Crohn's disease. Expert Opinion on Pharmacotherapy, 2015, 16, 63-78.	1.8	7
24	Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients. Journal of Clinical Virology, 2015, 66, 103-106.	3.1	10
25	Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 9675.	3.3	70
26	Advanced endoscopic imaging for surveillance for dysplasia and colorectal cancer in inflammatory bowel disease: Could the pathologist be further helped?. Saudi Journal of Gastroenterology, 2014, 20, 26.	1.1	6
27	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. Journal of Crohn's and Colitis, 2014, 8, 1217-1221.	1.3	53
28	Does glatiramer acetate provoke hepatitis in multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2014, 3, 266-268.	2.0	8
29	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. Digestive and Liver Disease, 2014, 46, 579-589.	0.9	40
30	Could JC virus provoke metastasis in colon cancer?. World Journal of Gastroenterology, 2014, 20, 15745.	3.3	20
31	Budesonide MMX and Mesalamine to Induce Remission in Patients With Ulcerative Colitis. Gastroenterology, 2013, 144, e23.	1.3	2
32	JC Virus, Helicobacter pylori, and Oesophageal Achalasia: Preliminary Results from a Retrospective Case–Control Study. Digestive Diseases and Sciences, 2013, 58, 1433-1434.	2.3	6
33	Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases. European Journal of Internal Medicine, 2013, 24, 385-392.	2.2	74
34	Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. Digestive and Liver Disease, 2013, 45, 986-991.	0.9	38
35	Could growth hormone play a role in Peutz Jeghers syndrome?. Medical Hypotheses, 2013, 81, 966-967.	1.5	5
36	Increased risk of pneumonia among patients with inflammatory bowel disease: A comparison between patients treated with biologic therapies and with conventional drugs. Journal of Crohn's and Colitis, 2013, 7, e405-e406.	1.3	5

#	Article	IF	CITATIONS
37	Comparing medical treatments for Crohn's disease. Journal of Comparative Effectiveness Research, 2013, 2, 135-149.	1.4	2
38	Mesalazine for the treatment of inflammatory bowel disease. Expert Opinion on Pharmacotherapy, 2013, 14, 1669-1678.	1.8	35
39	An Unusual Presentation of Zollinger-Ellison Syndrome. Case Reports in Gastroenterology, 2013, 7, 1-6.	0.6	6
40	The Role of Portal Vein Thrombosis in the Clinical Course of Inflammatory Bowel Diseases: Report on Three Cases and Review of the Literature. Gastroenterology Research and Practice, 2012, 2012, 1-7.	1.5	15
41	Psychopharmacological Treatment and Psychological Interventions in Irritable Bowel Syndrome. Gastroenterology Research and Practice, 2012, 2012, 1-11.	1.5	19
42	Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational study. Journal of Crohn's and Colitis, 2012, 6, 681-686.	1.3	52
43	An unusual presentation of T-lymphoma in a Crohn's disease patient treated with combo therapy: We are willing to take a risk of serious adverse events for a doubtful benefit?. Journal of Crohn's and Colitis, 2012, 6, 954-955.	1.3	2
44	Burden of Crohn's disease: economics and quality of life aspects in Italy. ClinicoEconomics and Outcomes Research, 2012, 4, 209.	1.9	13
45	Adalimumab in steroid-dependent Crohnʽs disease patients: Prognostic factors for clinical benefit. Inflammatory Bowel Diseases, 2012, 18, 826-831.	1.9	11
46	Multifocal Pyoderma Gangrenosum Resistant to Infliximab in Active Ulcerative Colitis: Don $\hat{E}\frac{1}{4}$ t Forget the Role of Cyclosporin. Inflammatory Bowel Diseases, 2012, 18, E1594-E1595.	1.9	10
47	A rare case of ulcerative proctitis associated with type B lymphomatoid papulosis and superimposed human cytomegalovirus infection. International Journal of Dermatology, 2012, 51, 838-839.	1.0	0
48	Randomized Controlled Trials in Perianal Crohn's Disease. Reviews on Recent Clinical Trials, 2012, 7, 297-302.	0.8	8
49	Methodology for high-quality studies on course and prognosis of inflammatory bowel disease. World Journal of Gastroenterology, 2012, 18, 3800.	3.3	2
50	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 30-35.	4.4	316
51	Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease. Journal of Crohn's and Colitis, 2011, 5, 173-174.	1.3	21
52	Unusual perforation after balloon dilation in a Crohn's disease patient: Report of a case. Journal of Crohn's and Colitis, 2011, 5, 269-270.	1.3	2
53	Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures. Digestive and Liver Disease, 2011, 43, 121-125.	0.9	68
54	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Diseasea †. Digestive and Liver Disease, 2011, 43, 1-20.	0.9	125

#	Article	IF	Citations
55	Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial. Digestive and Liver Disease, 2011, 43, 459-464.	0.9	10
56	Medical management of Crohn's disease. Expert Opinion on Pharmacotherapy, 2011, 12, 2505-2525.	1.8	17
57	Marked impact of <i>IL28B</i> genotype in the natural clearance of hepatitis C virus in patients with haemoglobinopathies. British Journal of Haematology, 2011, 154, 659-661.	2.5	7
58	Cancer in Crohn $\hat{E}\frac{1}{4}$ s Disease patients treated with infliximab: A long-term multicenter matched pair study. Inflammatory Bowel Diseases, 2011, 17, 758-766.	1.9	41
59	Smoking therapy may be an extreme cure in exsmokers with steroid-dependent and resistant ulcerative colitis. Inflammatory Bowel Diseases, 2011, 17, 2213.	1.9	4
60	Early postoperative recurrence of severe crohn $\hat{E}\frac{1}{4}$ s disease, with colonic involvement and associated human cytomegalovirus infection, treated with oral valganciclovir and adalimumab. Inflammatory Bowel Diseases, 2011, 17, E43-E44.	1.9	1
61	Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?. Current Drug Targets, 2011, 12, 1396-1405.	2.1	30
62	Natural history of cytomegalovirus infection in a series of patients diagnosed with moderate-severe ulcerative colitis. World Journal of Gastroenterology, 2011, 17, 633.	3.3	27
63	Oral valganciclovir for colonic dilatation in ulcerative colitis associated with human cytomegalovirus infection. Inflammatory Bowel Diseases, 2010, 16, 727-728.	1.9	2
64	An openâ€safety study of dual antiviral therapy in realâ€world patients with chronic hepatitis C. Pharmacoepidemiology and Drug Safety, 2010, 19, 1113-1123.	1.9	1
65	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 2010, 42, 1118-1125.	21.4	2,284
66	Over-expression of paneth cell-derived anti-microbial peptides in the gut of patients with ankylosing spondylitis and subclinical intestinal inflammation. Rheumatology, 2010, 49, 2076-2083.	1.9	43
67	Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease. Expert Review of Gastroenterology and Hepatology, 2010, 4, 709-712.	3.0	4
68	Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: An IG-IBD study. Journal of Crohn's and Colitis, 2010, 4, 291-300.	1.3	21
69	Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: Survival rate and prognostic factors. Digestive and Liver Disease, 2010, 42, 515-519.	0.9	17
70	Combined treatment with adalimumab and surgery in a patient with steroid-dependent Crohn's disease complicated by perianal disease. Digestive and Liver Disease Supplements, 2010, 4, 34-37.	0.2	0
71	Investigational agents for Crohn's disease. Expert Opinion on Investigational Drugs, 2010, 19, 1147-1159.	4.1	12
72	Gastrointestinal lesions associated with spondyloarthropathies. World Journal of Gastroenterology, 2009, 15, 2443.	3.3	42

#	Article	IF	CITATIONS
73	Incidence of HSV and HPV with azathioprine. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 444-445.	17.8	8
74	Infliximab prevents Crohn's disease recurrence after ileal resection. Expert Review of Gastroenterology and Hepatology, 2009, 3, 231-234.	3.0	2
75	Severe Cutaneous Psoriasis After Certolizumab Pegol Treatment: Report of a Case. American Journal of Gastroenterology, 2009, 104, 2867-2868.	0.4	23
76	Placebo therapy in Crohn's disease. European Journal of Internal Medicine, 2009, 20, 572-578.	2.2	7
77	Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology, 2009, 104, 514-524.	0.4	239
78	Is splenectomy a treatment option for aseptic abscesses in patients with Crohn $\hat{E}\frac{1}{4}$ s disease?. European Journal of Gastroenterology and Hepatology, 2009, 21, 1314-1316.	1.6	9
79	Familial mediterranean fever gene (MEVF) mutations in Crohn $\hat{E}^{1}\!\!/\!4$ s disease in a Mediterranean area. Inflammatory Bowel Diseases, 2008, 14, 1313.	1.9	3
80	Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use. Inflammatory Bowel Diseases, 2008, 14, 1168-1170.	1.9	21
81	Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease. Gastroenterology, 2008, 135, 1500-1509.	1.3	84
82	Prevalence of CARD15/NOD2 Mutations in the Sicilian Population. American Journal of Gastroenterology, 2008, 103, 248-249.	0.4	2
83	The Role of CARD15 Mutations and Smoking in the Course of Crohn's Disease in a Mediterranean Area. American Journal of Gastroenterology, 2008, 103, 649-655.	0.4	23
84	Occult Hepatitis B and Infliximab-induced HBV Reactivation. Inflammatory Bowel Diseases, 2007, 13, 508-509.	1.9	123
85	CA 19-9 to Rule Out Pancreatic or Biliary Cancer Among Patients with Cholestasis: An Unsuitable Test?. Digestive Diseases and Sciences, 2007, 52, 1125-1127.	2.3	7
86	Adalimumab Induction for Crohn's Disease. Gastroenterology, 2006, 130, 1929.	1.3	15
87	Postoperative maintenance therapy for inflammatory bowel disease. Current Opinion in Gastroenterology, 2006, 22, 377-381.	2.3	19
88	Leukocytapheresis in patients with moderate-severe steroid-dependant ulcerative colitis: Clinical Response without Endoscopic Response. Inflammatory Bowel Diseases, 2006, 12, 1009-1010.	1.9	1
89	Infliximab and ulcerative colitis. Expert Opinion on Biological Therapy, 2006, 6, 401-408.	3.1	11
90	Crohnʽs Disease: A Comparative Prospective Study of Transabdominal Ultrasonography, Small Intestine Contrast Ultrasonography, and Small Bowel Enema. Inflammatory Bowel Diseases, 2005, 11, 139-145.	1.9	115

#	Article	IF	CITATIONS
91	Intestinal Permeability and Genetic Determinants in Patients, First-Degree Relatives, and Controls in a High-Incidence Area of Crohn's Disease in Southern Italy. American Journal of Gastroenterology, 2005, 100, 2730-2736.	0.4	66
92	Complete Clinical Remission after High-Dose Immune Suppression and Autologous Hematopoietic Stem Cell Transplantation in Severe Crohn's Disease Refractory to Immunosuppressive and Immunomodulator Therapy. Inflammatory Bowel Diseases, 2004, 10, 892-894.	1.9	32
93	Familial Occurrence of Inflammatory Bowel Disease in Celiac Disease. Inflammatory Bowel Diseases, 2003, 9, 321-323.	1.9	30
94	Diagnostic Accuracy of Fecal Calprotectin Assay in Distinguishing Organic Causes of Chronic Diarrhea from Irritable Bowel Syndrome: A Prospective Study in Adults and Children. Clinical Chemistry, 2003, 49, 861-867.	3.2	192
95	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials. Radiology, 2002, 224, 47-54.	7.3	784
96	Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet, The, 2001, 358, 356-361.	13.7	553
97	The relationship between heritability and smoking habits in Crohn's disease. American Journal of Gastroenterology, 2000, 95, 3171-3175.	0.4	16
98	Treatment of Small Hepatocellular Carcinoma With Percutaneous Ethanol Injection: A Validated Prognostic Model. American Journal of Gastroenterology, 2000, 95, 2921-2927.	0.4	31
99	Mesalamine and relapse prevention in Crohn's disease. Gastroenterology, 2000, 119, 597.	1.3	68
100	Mortality and causes of death in celiac disease in a Mediterranean area. Digestive Diseases and Sciences, 1999, 44, 2538-2541.	2.3	67
101	Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trial. Gastroenterology, 1999, 116, 521-526.	1.3	113
102	Relationship between site of disease and familial occurrence in Crohn's disease. Digestive Diseases and Sciences, 1997, 42, 129-132.	2.3	25
103	Familial aggregation of inflammatory bowel disease in a Mediterranean area. European Journal of Epidemiology, 1996, 12, 205-210.	5.7	11
104	Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology, 1995, 108, 345-349.	1.3	197
105	No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Journal of Hepatology, 1995, 22, 522-526.	3.7	289
106	Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. Journal of Hepatology, 1994, 21, 1029-1034.	3.7	171
107	Smoking habits and recurrence in Crohn's disease. Gastroenterology, 1994, 106, 643-648.	1.3	417
108	Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology, 1992, 103, 363-368.	1.3	132

#	Article	IF	CITATIONS
109	FAMILIAL ASSOCIATION OF CROHN'S AND COELIAC DISEASES. Lancet, The, 1989, 334, 338.	13.7	23
110	Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. Gastroenterology, 1989, 96, 1566-1571.	1.3	115
111	Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Digestive Diseases and Sciences, 1988, 33, 47-51.	2.3	71
112	Ultrasonographic and radionuclide detection of hepatocellular carcinoma in cirrhotics with low alpha-fetoprotein levels. Cancer, 1984, 54, 2924-2926.	4.1	20